Figure 2.

Phase III outcome (▵▵HbA1c (%)) observations (black) and predictions across treatment arms. Method 1 (filled blue diamonds),¹⁷ Method 2 (filled red squares),¹⁴ Method 3 (open blue diamonds),¹⁷ Method 4 (open red triangles),¹⁸ Method 5 (filled green triangles).¹⁹ Vertical lines through 0 and −0.3% indicate no difference and noninferiority limits used for treatment comparisons. Left to right–top to bottom: 1) Insulin detemir vs. insulin glargine, 2) Biphasic insulin aspart vs. insulin glargine, 3) Liraglutide 1.8 mg + metformin + rosiglitazone vs. metformin + rosiglitazone, 4) Liraglutide 1.2 mg + metformin + rosiglitazone vs. metformin + rosiglitazone, 5) Liraglutide 0.6 mg + metformin vs. glimiperide + metformin, 6) Liraglutide 1.8 mg + metformin vs. glimiperide + metformin, 7) Metformin vs. glimiperide + metformin, 8) Liraglutide 1.2 mg + metformin vs. glimiperide + metformin.